美麗田園醫療健康(02373.HK)擬3.5億元收購廣州奈瑞兒健康諮詢70%股權
格隆匯3月26日丨美麗田園醫療健康(02373.HK)公吿,於2024年3月26日,買方廣州美麗田園健康研究有限公司(公司全資附屬公司)訂立投資協議,據此(其中包括),賣方奈瑞兒健康科技有限公司有條件同意出售,而買方有條件同意收購目標股權(佔目標公司廣州奈瑞兒健康諮詢有限公司全部股權的70%),代價為人民幣3.5億元。
賣方目前的主要業務為經營奈瑞兒品牌。按2021年收入計算,奈瑞兒是中國第二大傳統美容服務提供商1。本次交易共涉及80家美容及保健服務門店、6家醫療美容門診(其中一家同時經營亞健康醫療業務)及2家中醫門診,上述門店主要位於廣州及深圳地區。於完成後,目標公司將擁有奈瑞兒品牌並直接經營上述門店。
根據目標公司的未經審核備考財務資料,其截至2023年12月31日止年度的收入及淨利潤分別約為人民幣514.4百萬元及人民幣33.4百萬元。收購事項將增厚公司收入及利潤,顯著提升市場佔有率,在獨創的三美商業模式下,收購事項將為集團長期增長注入新動能。
美麗田園在中國美麗與健康服務行業經營超30年。集團堅持通過內生增長及戰略性收購拓展業務規模,擁有豐富的行業收購整合經驗。於2014年至今,集團持續探索行業整合機會,併成功完成超過20項美容和保健行業的收購。
同時,集團在連鎖企業管理、數字化轉型、客户運營管理、產品創新等領域具備豐富經驗,將用於賦能目標公司經營管理。此次收購奈瑞兒品牌將是集團外延增長的一大重要舉措,集團將實現門店網絡擴張及會員基數增長,通過發揮集團獨創的三美商業模式優勢,進一步提升收入水平,構建滿足客户全生命週期需求的美麗和健康業務生態。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.